12:00 AM
 | 
Oct 06, 2008
 |  BC Week In Review  |  Company News  |  Deals

ImClone deal

ImClone said the unnamed suitor behind a $70 per share acquisition bid has completed due diligence and made a proposal. The biotech said negotiations...

Read the full 98 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >